Sulfestrol for treating cancer
AssigneeChamaeleo Pharma Bvba
InventorsJohannes Jan PLATTEEUW, Martijn DE BREE, Edwin KLUMPER
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of Sulfestrol (diethylstilbestrol sulfate) in a method of curative or palliative treatment of cancer in a mammal. The inventors have unexpectedly found that Sulfestrol can suitably be employed as an effective drug in the treatment of cancer in mammals. The inventors have further discovered that Sulfestrol can be administered even in high dosages without giving rise to serious side effects. Besides the clinical use of Sulfestrol the present invention also relates to oral dosage units comprising Sulfestrol and to sterile liquids for intravenous administration that comprise Sulfestrol.
Claims13
A method of curative or palliative treatment of breast cancer or prostate cancer in a mammal, comprising administering daily to the mammal at least 0.03 mmol of a mono-sulfestrol (diethylstilbestrol-monosulfate) selected from the group consisting of 4-(4-(4-oxidophenyl)hex-3-en-3-yl)phenyl sulfate, pharmaceutically acceptable salts and esters thereof, other than 4,4′-(hex-3-ene-3,4-diyl)bis(4,1-phenylene) disulfate, wherein the administration is oral and/or intravenous.
5-6. (canceled)
(canceled)
An oral dosage unit comprising at least 0.003 mmol of mono-sulfestrol, wherein the mono-sulfestrol is not diethylstilbestrol mono[35S]sulfate.
(canceled)
A sterile aqueous liquid for intravenous administration, comprising at least 0.1 μmol/ml of mono-sulfestrol other than diethylstilbestrol mono[35S]sulfate.
Dependencies are inferred from the claim text.